SecondWave Systems

SecondWave Systems operates at the intersection of medical devices, digital health, and therapeutic neuromodulation. Its stated approach uses non-invasive, low-intensity focused ultrasound to influence nerves, cells, and organs, with potential applications including inflammation, pain, and other disorders. The company also describes wearable and in-home treatment concepts, alongside sensing and imaging capabilities intended to support personalized therapy. The company’s disclosed backing includes a $7 million Series A led by Treo Ventures in April 2025 and an expanded Series A with Sectoral Asset Management joining in October 2025. Its Health Care classification and employee range of 11–50 indicate a relatively small company developing a specialized therapeutic platform, rather than a broadly scaled medical-device operator.

SecondWave Systems’ disclosed financing history indicates continued support for development of its ultrasound therapy platform, but the reported totals and individual round amounts do not reconcile. The structured company data lists $10 million in total funding, while the listed Seed, grant, and April 2025 Series A amounts sum to $17 million before the October 2025 expanded Series A, whose amount is undisclosed. The company raised $7 million in a Seed round in April 2021, received a $3 million grant in March 2024, and raised a further $7 million in a Series A led by Treo Ventures on April 8, 2025. On October 22, 2025, it announced an expanded Series A and the addition of Sectoral Asset Management, without disclosing the incremental amount. Its employee band is 11–50, and a general hiring notice indicates open roles without specifying functions or headcount targets. The available evidence supports a development-stage trajectory, but does not establish revenue, clinical progress, or the pace of scaling.